The introduction of generic drugs, which have a chemically identical active ingredient to a brand-name drug on which patent protection has expired, has saved enormous amounts of money on drug spending. Over 85% of all prescriptions are now for generics. Biosimilars are intended to provide a generic for biologic therapies. But since those products are more complex, the cost and process for developing them is higher. And of course the drug companies are playing their usual games to prevent competition. A brief from the Pacific Research Institute’s Center for Medical Economics and Innovation explores potential savings if there was greater use of biosimilars. (Pac. Res. Paper) Off a baseline of all original biologic use, currently we are saving about $250 million through use of biosimilars. There are only 9 current therapies where a biosimilar is approved. If just for those categories, biosimilar use rose to 25%, we would save $2.5 billion, at 50% $4.8 billion and at 75%, $7.2 billion. While there may be clinical reasons why biosimilar usage would not be 100%, it should get close to that. And if biosimilar use grows dramatically, prices for those biosimilars should come down, providing even greater savings. Biosimilar development has been thwarted by drug company lobbying and lawsuits and by payoffs to biosimilar developers. Congress and the FDA need to take stronger action to facilitate, even subsidize biosimilar development and to allow payers to require their use except when clinically inappropriate. Europe has been much more aggressive in approving biosimilars and has reaped substantial savings. We should do the same.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
What do you get when you combine a company with a commodity business model, that out of desperation massively overpays for another company that has a commodity business model? $10...
July 27, 2022
The “stupid” model for health care venture capital investing is alive and well. Everside health, which operates primary care clinics and has grown by acquiring other failing health care businesses,...
July 26, 2022
Apparently not even a cute name can save you if you have a stupid business. I constantly bemoan the mis-application of capital and health care is Exhibit A. Olive, another...
July 26, 2022
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace